Full Breakdown
Pentagon Mandates Annual Testosterone Screening for Service Members 30 and Older
7/16/2026, 12:30:07 AM
Core Policy Announcement
On Wednesday, July 15 2026, Defense Secretary Pete Hegseth announced that the Department of Defense will require annual testosterone-deficiency screenings for all active-duty personnel age 30 and older as part of their routine periodic health assessment. Service members under 30 may be screened voluntarily. If a medical evaluation recommends testosterone replacement therapy (TRT), participation will be optional.
Background and Policy Context
The screening order arrives amid a broader Trump-administration push to expand access to testosterone therapy. Earlier in 2026, Health Secretary Robert F. Kennedy Jr. and the Food and Drug Administration (FDA) signaled intent to loosen prescribing limits for testosterone gels, patches, pills and injections. The administration has also removed a black-box warning linking testosterone to heart attacks and strokes. Hegseth framed the new requirement as a health-readiness measure rather than a performance-enhancement program.
Prevalence Data
- 5.6 % of men 30-79 are estimated to have testosterone deficiency (The Hill).
- 2 % of American men are reported to experience low testosterone (American Urology Care Foundation, cited by Business Insider).
- The Endocrine Society notes that low testosterone can cause fatigue, muscle loss, weight gain and mood changes.
Official Statements and Responses
Secretary Hegseth emphasized that the initiative “is not about artificial enhancement” but about “restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight.” He added that the Department of Defense “has a sacred duty to maintain that advantage” and that “we owe our warriors the absolute best medical care in the world.” The Pentagon declined to provide a rollout timeline, details on testing methodology, or whether female service members will receive analogous hormone assessments.
Criticism and Opposition
Dr. Snyder, a researcher who led major NIH testosterone trials, warned that low testosterone is “very rare, even up to age 79, with only a 2 percent incidence rate,” and that routine screening is not recommended. He stressed that testing should be limited to individuals with symptoms and that the required three-morning, fasted measurements would be difficult to execute in a military setting, increasing the risk of overdiagnosis. Snyder also highlighted serious TRT risks—including atrial fibrillation, pulmonary emboli and fractures—citing the TRAVERSE trial. Additionally, Rep. Chrissy Houlahan (D-PA) criticized the policy as “taking direction from the far corners of the manosphere” and called for equal testing and treatment options for women.
Conflicting Reports and Gaps
Sources differ on the prevalence of low testosterone (2 % vs. 5.6 %). The Pentagon has not clarified whether the screening will include estrogen assessments for female personnel or how treatment costs will be covered. No specific implementation date has been disclosed, and the policy’s alignment with existing medical guidelines— which advise against blanket testing—remains uncertain.
Verbatim Quotes
- “I'm authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best,” — Pete Hegseth
- “This initiative — it’s not about artificial enhancement; it’s about restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight,” — Pete Hegseth
- “Screening is recommended only for symptoms suggestive of low testosterone,” — Dr. Snyder
- “Testosterone treatment is not approved for women under any circumstances.” — Dr. Snyder
What’s Next
The 2025 National Defense Authorization Act directed the Pentagon to brief Congress on low-testosterone treatments and screening protocols, but no further congressional hearing dates have been announced. The Department of Defense has indicated that additional guidance will be issued in the coming weeks, though the exact start of mandatory testing remains unspecified.
